New obesity drug combo shows promise in curbing appetite
NCT ID NCT06207877
First seen Jan 11, 2026 · Last updated Apr 25, 2026 · Updated 14 times
Summary
This study tested whether a combination of two medicines, cagrilintide and semaglutide (called CagriSema), can reduce how much people with overweight or obesity eat and how hungry they feel. 62 participants were randomly assigned to receive either CagriSema or a placebo for about 32 weeks. The main goal was to measure changes in energy intake during meals and overall appetite.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Parexel International GmbH
Berlin, 14050, Germany
Conditions
Explore the condition pages connected to this study.